ArticleInternational journal of cardiology. Heart & vasculature2026
Long-term outcome of heart failure patients with improved ejection fraction: Results from a real-world registry.
Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This real-world cohort study aims to elucidate the characteristics and long-term outcome of heart failure patients with improved ejection fraction (HFimpEF). Methods: Data from a prospective observational single-center registry were analyzed. Adult patients with reduced left ventricular ejection fraction (LVEF)(≤40%) were classified as HFimpEF if follow-up LVEF improved to >40%. Primary outcome was defined as the composite of all-cause death, left ventricular assist device implantation, or heart transplantation. Results: We identified 207 HFimpEF patients (33%) among 635 HF patients with reduced LVEF. Their LVEF improved from 27% (interquartile range, IQR 21,34) to 45% (IQR 43,50, Conclusions: The cardiovascular long-term outcome of HFimpEF patients was generally favorable, with most deaths due to non-cardiovascular causes. A history of cancer and an elevated E/e' ratio independently predicted the composite of death and advanced HF therapy. Future trials are warranted to determine the optimal long-term pharmacotherapeutic management of this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.